A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
An open-label, single-arm, multicenter, prospective clinical study of Hanlikang and BTK inhibitors in the treatment of newly diagnosed mantle cell lymphoma
Newly Diagnosed Mantle Cell Lymphoma
DRUG: Rituximab
progression free survival（PFS）, progression free survival, two years
ORR, objective remission rate, two years|CRR, complete remission rate, two years|OS, overall survival, two years|ADR, adverse drug reaction, two years
An open-label, single-arm, multicenter, prospective clinical study of Hanlikang and BTK inhibitors in the treatment of newly diagnosed mantle cell lymphoma